EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacokinetics-Based Safety Evaluation in Half-Dose Verteporfin Photodynamic Therapy

Hyeong Min Kim, Hyuncheol Kim, Jae Yong Chung, Se Joon Woo

Ophthalmic Research · 2024

DOI: 10.1159/000541619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmic Research, 2024. Verfasst von Hyeong Min Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Verteporfin, Photochemotherapy, Photosensitizing Agents. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study was conducted to assess the systemic pharmacokinetic profiles of half-dose verteporfin photodynamic therapy (PDT) using concentration data from a previous clinical trial and to subsequently suggest safety precaution guidelines.

Methods

Coefficients for the bi-exponential model were obtained from published data on post-infusion plasma verteporfin concentrations within a period of 0.17–4 h. Using the extrapolative forecasting method, we plotted the 48-h post-verteporfin plasma concentration model. The time required to achieve a comparable level of verteporfin 48 h after a conventional dose (6 mg/m2 body surface area, BSA) infusion was calculated for a half-dose infusion (3 mg/m2 BSA).

Results

At 24 and 48 h post-verteporfin infusion, the plasma concentration following the conventional dose was 1.28 × 10−4 µg/mL and 5.06 × 10−8 µg/mL, compared to 3.57 × 10−5 µg/mL and 7.54 × 10−9 µg/mL for the half-dose PDT, representing concentrations that were 3.6 times and 6.7 times higher, respectively. The estimated time required to attain the same level of verteporfin 48 h after a conventional dose was calculated as 42-h post-half-dose PDT.

Conclusions

The results of this study indicate that precautionary measures should be taken to avoid sunlight following both half and conventional doses of PDT during the similar post-treatment periods of two days. Nevertheless, given the substantially higher plasma concentration levels associated with conventional-dose PDT compared with the half-dose, systemic safety should be carefully considered when administering conventional-dose PDT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VerteporfinPhotochemotherapyPhotosensitizing AgentsHumansMaleMacular DegenerationFemalePorphyrinsDose-Response Relationship, Drug

Stichwörter der Autor:innen

PharmacokineticsPhotodynamic therapyPhotosensitivityVerteporfin

Substanzen

VerteporfinPhotosensitizing AgentsPorphyrins

Autor:innen und Institutionen

  • Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Ophthalmology, Konkuk University School of Medicine, Seoul, Republic of Korea.
  • Chemical and Biomolecular Engineering, Sogang University, Seoul, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

Zitieren

APA

Kim, H. M., Kim, H., Chung, J. Y., & Woo, S. J. (2024). Pharmacokinetics-Based Safety Evaluation in Half-Dose Verteporfin Photodynamic Therapy. Ophthalmic Research. https://doi.org/10.1159/000541619

Vancouver

Kim HM, Kim H, Chung JY, Woo SJ. Pharmacokinetics-Based Safety Evaluation in Half-Dose Verteporfin Photodynamic Therapy. Ophthalmic Research. 2024. doi:10.1159/000541619

BibTeX
@article{Kim2024,
  author = {Kim, Hyeong Min and Kim, Hyuncheol and Chung, Jae Yong and Woo, Se Joon},
  title = {Pharmacokinetics-Based Safety Evaluation in Half-Dose Verteporfin Photodynamic Therapy},
  journal = {Ophthalmic Research},
  year = {2024},
  doi = {10.1159/000541619}
}
Kostenlos starten →